Relay Therapeutics, Inc.

Relay Therapeutics, Inc. (NASDAQ: RLAY) is a clinical-stage biopharmaceutical company focused on developing precision medicine therapies for patients with cancer and genetic diseases. The company operates through its proprietary Dynamo platform, which integrates computational and experimental approaches to identify and drug protein targets that have historically been difficult to address using conventional drug discovery methods. This Motion-Based Drug Design approach represents a fundamental shift from industry-standard static protein structures to a dynamic understanding of protein behavior, enabling the discovery of medicines with greater specificity and potency.

The company's lead product candidate, zovegalisib (RLY-2608), is the first known allosteric, pan-mutant and isoform-selective phosphoinositide 3-kinase alpha inhibitor in clinical development. Zovegalisib is being evaluated in multiple clinical programs, including the ReDiscover Trial for patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer, and the ReInspire Trial for patients with PIK3CA-related overgrowth spectrum and vascular anomalies. In February 2026, the FDA granted Breakthrough Therapy designation to zovegalisib in combination with fulvestrant for advanced breast cancer patients who have progressed on CDK4/6 inhibitors. The company initiated a Phase 3 registrational study, ReDiscover-2 Trial, in the second quarter of 2025.

Beyond zovegalisib, Relay Therapeutics is advancing additional pipeline programs including RLY-8161, an NRAS-selective inhibitor for NRAS-mutated solid tumors, and a non-inhibitory chaperone for Fabry disease. The company also maintains early-stage discovery programs across precision oncology and genetic diseases. In December 2024, Relay Therapeutics entered into an exclusive global licensing agreement with Elevar Therapeutics for lirafugratinib, its FGFR2 inhibitor, transferring development and commercialization rights for that program.

The company collaborates with strategic partners including Pfizer on clinical development of zovegalisib combinations and D. E. Shaw Research on computational modeling. As a clinical-stage company, Relay Therapeutics has not generated revenue from product sales and continues to incur significant operating losses while advancing its pipeline toward regulatory approval and commercialization.